What project PT4 buys
The Protect Advanced Component Development and Prototypes (ACD&P) Project provides the ability to shield the Joint Force from harm caused by chemical and biological (CB) hazards by preventing or reducing individual and collective exposures, applying prophylaxis to prevent or mitigate negative physiological effects, and protecting critical equipment. Efforts included in this Project are: (1) Accelerated Antibodies - Enhanced Biological Defense (AA-ENBD) (2) Biological Containment Isolation System - Enhanced Biological Defense (BCIS-ENBD) (3) Generative Unconstrained Intelligent Drug Engineering-Enhanced Biological Defense (GUIDE-ENBD) (4) Medical Countermeasures Platform Technologies (MCMPT) - Prevention Platform (5) MCMPT - Host Directed Countermeasure (6) Plague Monoclonal Antibodies (PLG MAB) (7) Prophylactic Technology Systems (ProTecS) (8) Vaccine Acceleration by Modular Progression - Enhanced Biological Defense (VAMP-ENBD) (9) Portable Patient Transport System - Enhanced Biological Defense (PPTS-ENBD) (10) Shipboard Isolation System (SIS)
- Product Development
- Support
- Test and Evaluation
- Management Services
Project PT4 funding, FY2025–FY2031
Prior years are actuals, the budget year is the request, and the outyears are the FYDP plan. Estimate types are colored and never summed into one figure. Projects carry the full five-year plan; the activities inside them stop at the budget year.
| Fiscal Year | Estimate Type | Amount ($M) |
|---|---|---|
| FY2025 | Actual | 170.6 |
| FY2026 | Enacted | 158.0 |
| FY2027 | Request | 129.2 |
| FY2028 | Outyear | 100.1 |
| FY2029 | Outyear | 77.4 |
| FY2030 | Outyear | 78.3 |
| FY2031 | Outyear | 83.2 |
10 accomplishments / planned programs
The R-2A exhibit — the only level of the budget that describes work that has not happened yet. Activities carry the prior, current and budget year only, no five-year plan. 3 of them describe FY2027 work in enough detail to have their own page; the rest are shown here in full. Coverage is partial across the corpus, so count activities, never total them.
Continue planning, coding, building, and testing new and existing digital tools and corresponding experimental capabilities to increase speed and accuracy of computational medical countermeasure (MCM) discovery efforts to enable rapid response capability. Continue design of new MCMs for transition to the Rapid Access to Products in…
Read the FY2027 plan →Complete phase 1 clinical studies follow-ups for prototype two, continue clinical studies for prototype three, complete manufacturing and preclinical studies for prototype four and submit Investigational New Drug package to Food and Drug Administration for approval to execute a phase 1 clinical study.
Read the FY2027 plan →Continue development and manufacturing of multiple vaccine candidates against biothreats. Continue test and evaluation efforts in safety and efficacy clinical trials.
Read the FY2027 plan →FY2027 planned work Execute current GMP to produce phase 2 compliant doses for use in an emergency situation. Complete non-clinical testing to support Investigational New Drug filing to the FDA. Prepare for phase 1 clinical trial execution.
FY2026 to FY2027 change Minor increase due to planned scope of preparation activities required prior to execution of phase 1 clinical trial.
FY2026 plans — current year Continue development of host directed medical countermeasure through Good Manufacturing Practices (GMP) and non-clinical testing to support an Investigational New Drug submission to the Food and Drug Administration (FDA) and start of Phase 1 clinical trial.
FY2025 accomplishments Initiated development of host directed platform MCM program and improve delivery system to provide instant and long-lasting prophylactic protection against viral, bacterial and/or toxin threats.
FY2027 planned work Initiate non-clinical trials in first candidate from industry.
FY2026 to FY2027 change Increased investment enables improved broad spectrum nerve agent prophylaxis development through a next generation initiative providing a pipeline of maturation of industry candidates, enabling protective medical countermeasure solutions.
FY2027 planned work Complete optimization of platform performance, conduct annual exercises to validate platform activity, and prepare for potential transition activities in FY 2028.
FY2026 to FY2027 change Increase is due to routine program adjustments and integration with Host Directed Countermeasure efforts within MCMPT.
FY2026 plans — current year Continue optimization of platform performance and to conduct annual exercises to validate platform maturity.
FY2025 accomplishments Continued Prevention Platform development to improve efficiency and response time of the platform in developing and optimizing medical countermeasures against novel threats.
FY2027 planned work Complete phase 1a patient follow ups. Transition data products to Rapid Access to Products in Development. Initiate transition of products for potential further clinical evaluation to expand the safety database for use in an emergency situation.
FY2026 to FY2027 change Program/project is entering completion and all activities will be closed. Decrease due to program entering last year of effort, executing wrap up activities and program close out.
FY2026 plans — current year Complete the Phase 1 Clinical study and initiate the Phase 1b study.
FY2025 accomplishments Completed and delivered 5,000-10,000 phase 2 compliant doses of PLG MAB product for use in an emergency. Obtained Investigational New Drug filing from Food and Drug Administration to initiate phase 1 clinical trial to evaluate safety. Initiated phase 1 clinical trial.
FY2026 to FY2027 change BCIS-ENBD will transition from a Major Capability Acquisition (MCA) to a Middle Tier Acquisition (MTA) program in 3Q FY 2026 pending approval.
FY2026 plans — current year Complete activities to achieve successful Middle Tier of Acquisition Rapid Prototyping (MTA-RP) decision in 3Q FY 2026.
FY2025 accomplishments Completed closeout activities from concept development demonstration.
FY2025 accomplishments Completed closeout activities from concept development demonstration.
FY2025 accomplishments Completed closeout activities from concept development demonstration and continued test planning.
Named performers on project PT4
Performers named in the R-3 exhibit under this project. Share is of the project's whole FY2027 R-3 total — the same denominator the program-element split uses, so the two read on one scale and will not sum to 100% when unnamed or government work is in the mix. Budget-justification contract funding, not obligations.